ATE391791T1 - Membran penetrierende peptide und deren anwendungen - Google Patents

Membran penetrierende peptide und deren anwendungen

Info

Publication number
ATE391791T1
ATE391791T1 AT01964392T AT01964392T ATE391791T1 AT E391791 T1 ATE391791 T1 AT E391791T1 AT 01964392 T AT01964392 T AT 01964392T AT 01964392 T AT01964392 T AT 01964392T AT E391791 T1 ATE391791 T1 AT E391791T1
Authority
AT
Austria
Prior art keywords
penetrating peptides
membrane
applications
interest
membrane penetrating
Prior art date
Application number
AT01964392T
Other languages
English (en)
Inventor
Yong Guo
Clarence Morse
Zhengbin Yao
George Keesler
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0103110.3A external-priority patent/GB0103110D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE391791T1 publication Critical patent/ATE391791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
AT01964392T 2000-08-25 2001-08-23 Membran penetrierende peptide und deren anwendungen ATE391791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1

Publications (1)

Publication Number Publication Date
ATE391791T1 true ATE391791T1 (de) 2008-04-15

Family

ID=26245698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964392T ATE391791T1 (de) 2000-08-25 2001-08-23 Membran penetrierende peptide und deren anwendungen

Country Status (9)

Country Link
EP (1) EP1360311B1 (de)
AT (1) ATE391791T1 (de)
AU (1) AU8524901A (de)
CA (1) CA2420350C (de)
IL (1) IL154589A0 (de)
MX (1) MXPA03001622A (de)
NO (1) NO332050B1 (de)
NZ (1) NZ524386A (de)
WO (1) WO2002018572A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086927A1 (en) 1995-11-01 2003-05-08 University Of Southern California Expression of cyclin G1 in tumors
ATE388720T1 (de) 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
FR2781674B1 (fr) * 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
US7432349B2 (en) * 2002-01-23 2008-10-07 The United States Of America As Represented By The Department Of Health And Human Services Tumor suppressor gene, p28ING5
EP1496927A4 (de) * 2002-01-29 2007-09-12 Aventis Pasteur Zielimmunogene
KR20030078115A (ko) * 2002-03-28 2003-10-08 (주)코아바이오텍 펩타이드 유전자 전달매체 및 이를 이용한 유전자 전달 방법
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1699492A2 (de) * 2003-12-31 2006-09-13 Sanofi Pasteur Inc. Zielimmunogene
JP5043672B2 (ja) 2005-10-28 2012-10-10 田辺三菱製薬株式会社 新規細胞膜透過ペプチド
WO2007071448A2 (en) * 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US8603967B2 (en) 2009-07-29 2013-12-10 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
JP5858284B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメントとその利用
WO2011052679A1 (ja) 2009-11-02 2011-05-05 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
JP5854283B2 (ja) 2010-06-04 2016-02-09 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
KR101671114B1 (ko) 2015-06-26 2016-10-31 충북대학교 산학협력단 Ｕｌｋ２로부터 유래된 핵 위치화 신호 펩타이드 및 이의 용도
MX2024001708A (es) * 2021-08-06 2024-04-23 Univ Pennsylvania Composiciones y métodos para tratamiento y prevención de proteínas mal plegadas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
AU7022998A (en) * 1997-04-28 1998-11-24 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
CA2392490A1 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
CN1254234C (zh) * 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中

Also Published As

Publication number Publication date
NO332050B1 (no) 2012-06-11
EP1360311A2 (de) 2003-11-12
AU8524901A (en) 2002-03-13
NO20030856D0 (no) 2003-02-24
WO2002018572A3 (en) 2003-09-12
CA2420350A1 (en) 2002-03-07
NO20030856L (no) 2003-04-24
CA2420350C (en) 2010-07-13
EP1360311B1 (de) 2008-04-09
NZ524386A (en) 2005-10-28
WO2002018572A2 (en) 2002-03-07
MXPA03001622A (es) 2004-09-06
IL154589A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
ATE391791T1 (de) Membran penetrierende peptide und deren anwendungen
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
HUP0301842A2 (hu) Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE380539T1 (de) Hautpflegezusammensetzungen, die silikonelastomere enthalten
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
HUP9902952A1 (hu) Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása
BR9813740A (pt) Teriparatìdeo cristalino
ATE312172T1 (de) Immunschützendes influenzaantigen und dessen verwendung zur impfung
EA201070548A1 (ru) Производные кератина и способы их получения
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
NO20031860D0 (no) Kahalaolid F
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE482975T1 (de) Nukleinsäuremoleküle zur kodierung cyclisierbare aminosäuresequenzen
AU2002326070A1 (en) Peyers's patch and/or m-celle targeting ligands
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
ATE491719T1 (de) Peptidinhibitoren gegen den eintritt von hiv in zellen
AU1393301A (en) Method for encapsulating proteins or peptides in liposomes, liposomes produced using said method, and their use
CY1108643T1 (el) Κυτταρικη σειρα και χρησεις της

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties